Literature DB >> 1898737

Synthesis and secretion of plasminogen activator inhibitor 1 by human endothelial cells in vitro. Effect of active site mutagenized tissue-type plasminogen activator.

K Bartha1, P J Declerck, H Moreau, L Nelles, D Collen.   

Abstract

The effects of recombinant tissue-type plasminogen activator (rt-PA) and of an inactive mutant of rt-PA, obtained by mutagenesis of the active site Ser478 to Ala (rt-PA-Ala478), on the synthesis and secretion of plasminogen activator inhibitor-1 (PAI-1) by human umbilical vein endothelial cells (HUVEC) in culture were studied. Under base-line conditions, PAI-1 antigen secretion was 4.3 +/- 1.0 micrograms (mean +/- S.D., n = 8) per 10(6) cells in 24 h. This PAI-1 had a low specific activity (6,000 +/- 1,600 units/mg) and Mr of 50,000, which was not altered by addition of rt-PA. In HUVEC cultured with 2 micrograms/ml rt-PA-Ala478, PAI-1 antigen secretion was 2.1 +/- 0.8 micrograms (n = 5) per 10(6) cells in 24 h with a specific activity of 120,000 +/- 42,000 units/mg and Mr of 50,000. Addition of rt-PA to this conditioned medium resulted in generation of three main components: 16% migrated as an Mr 106,000 rt-PA.PAI-1 complex, 16% as an Mr 81,000 degraded rt-PA.PAI-1 complex and the remainder as an Mr 45,000 degradation product of PAI-1. HUVEC cultured with 2 micrograms/ml rt-PA secreted 3.9 +/- 0.6 micrograms (n = 8) PAI-1 antigen per 10(6) cells within 24 h, of which 20-50% occurred as intact or degraded complexes with t-PA (Mr 106,000 and 81,000) and the rest as an inactive Mr 45,000 degradation product of PAI-1. PAI-1 mRNA levels, determined by Northern blot analysis and expressed relative to beta-actin mRNA levels, were very similar for HUVEC cultured in the absence or the presence of rt-PA or rt-PA-Ala478. It is concluded that PAI-1 is secreted by HUVEC in culture in fully active form which spontaneously inactivates. PAI-1 can be stabilized by addition of rt-PA-Ala478 to the culture medium, resulting in a 20-fold increase in specific activity. Interaction of rt-PA with active PAI-1 produces both t-PA.PAI-1 complex and an inactive degradation product of PAI-1.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898737

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  Vitronectin and Its Interaction with PAI-1 Suggests a Functional Link to Vascular Changes in AMD Pathobiology.

Authors:  Fabiola Biasella; Tobias Strunz; Christina Kiel; Bernhard H F Weber; Ulrike Friedrich
Journal:  Cells       Date:  2022-05-27       Impact factor: 7.666

2.  Remarkable stabilization of plasminogen activator inhibitor 1 in a "molecular sandwich" complex.

Authors:  Galina Florova; Sophia Karandashova; Paul J Declerck; Steven Idell; Andrey A Komissarov
Journal:  Biochemistry       Date:  2013-06-25       Impact factor: 3.162

3.  Structural Insights into the Mechanism of a Nanobody That Stabilizes PAI-1 and Modulates Its Activity.

Authors:  Machteld Sillen; Stephen D Weeks; Sergei V Strelkov; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2020-08-15       Impact factor: 5.923

4.  Altered Protein Function Caused by AMD-associated Variant rs704 Links Vitronectin to Disease Pathology.

Authors:  Fabiola Biasella; Karolina Plössl; Claudia Karl; Bernhard H F Weber; Ulrike Friedrich
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-12-01       Impact factor: 4.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.